摘要
目的探讨喹硫平作为增效药治疗难治性抑郁症的疗效与安全性。方法选取58例难治性抑郁障碍患者[汉密尔顿抑郁量表(HAMD)≥17分],在原用药物治疗基础上合并使用喹硫平,起始剂量50 mg.d-1,根据个体疗效和耐受情况调整剂量,最大剂量为375 mg.d-1;治疗8周。采用HAMD、汉密尔顿焦虑量表(HAMA)及不良反应评定量表(TESS)分别在治疗前及治疗第1,2,4和8周末各评定1次,并进行对比分析。结果治疗第8周HAMD量表为(8.3±5.4)分,HAMA量表为(6.0±4.7)分,与使用喹硫平前[分别为(26.8±8.6)和(17.8±5.3)分]比较均差异有显著性(均P<0.01)。在研究终点共有35例患者痊愈,11例患者显效,显效率82.1%;不良反应程度较轻微,有2例患者因过度镇静提前退出试验,大部分患者均可耐受。结论中、小剂量喹硫平可作为常规抗抑郁增效药治疗难治性抑郁症。
Objective To explore effects and safety of quetiapine as synergist on refractory major depression. Methods 58 patients with the refractory major depression（ HAMD≥17） were treated with former antidepressants combined with quetiapine for 8 weeks. Its beginning dosage was 50 mg·d^-1 and gradually increased to top dosage 375 mg·d^-1 by individual effects and tolerance. Comparing assessments was carried out before treatment, and at the end of the I st ,2nd ,4th, and 8th week after treatment by Hamilton Rating Scale for Depression （ HAMD ）, Hamilton Rating Scale for Anxiety （ HAMA ） and Treatment Emergent Symptoms Scale（TESS）. Results At the end of the 8th week of the study, the total scores of HAMD （ 8.3±5.4） and HAMA （6.0±4.7 ） showed significant difference compared with that of （ 26.8±8.6 ） and （17.8±5.3 ）, repectively before treatment （ P〈 0.01）, In the end of study, 35 patients achieved completely remission, and 11 patients showed well response, the marked improved rate was 82.1%. Side effects induced by quetiapine were mild and tolerable. Only 2 patients dropped out because of over sedation. Conclusion Small dose of quetiapine can be used as synergist of antidepressants for the routine treatment of refractory major depression.
出处
《医药导报》
CAS
2007年第11期1308-1310,共3页
Herald of Medicine
关键词
喹硫平
抑郁症
难治性
增效药
Quetiapine
Depression , refractory
Synergist
作者简介
刘力（1970-），女，辽宁辽中人，硕士，主治医师，研究方向：精神疾病的临床及脑电生理学研究。电话：（0）13386886236;E-mail：ykdx@sohu.com
